Do analysts rate NIVF or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NIVF or MGRX?

NewGenIvf Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.47 $9.88M N/A N/A Mangoceuticals $460K 18.89 -$20.64M -$1.01 N/A

Does the media refer more to NIVF or MGRX?

In the previous week, NewGenIvf Group and NewGenIvf Group both had 3 articles in the media. NewGenIvf Group's average media sentiment score of 0.96 beat Mangoceuticals' score of 0.96 indicating that NewGenIvf Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NIVF or AIDX?

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 792.86%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than NewGenIvf Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, NIVF or AIDX?

NewGenIvf Group has higher revenue and earnings than 20/20 Biolabs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.47 $9.88M N/A N/A 20/20 Biolabs $2.05M 3.49 -$3.74M -$0.54 N/A

Is NIVF or AIDX more profitable?

Company Net Margins Return on Equity Return on Assets NewGenIvf Group N/A N/A N/A 20/20 Biolabs N/A N/A N/A

Do analysts rate NIVF or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NIVF or BMGL?

NewGenIvf Group has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.47 $9.88M N/A N/A Basel Medical Group $8.90M 0.82 -$9.50M N/A N/A

Is NIVF or BMGL more profitable?

Company Net Margins Return on Equity Return on Assets NewGenIvf Group N/A N/A N/A Basel Medical Group N/A N/A N/A

Does the media favor NIVF or BMGL?

In the previous week, NewGenIvf Group had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for NewGenIvf Group and 2 mentions for Basel Medical Group. NewGenIvf Group's average media sentiment score of 0.96 beat Basel Medical Group's score of 0.94 indicating that NewGenIvf Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Basel Medical Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NIVF or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, NIVF or BIAF?

NewGenIvf Group has higher earnings, but lower revenue than bioAffinity Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.47 $9.88M N/A N/A bioAffinity Technologies $6.16M 0.77 -$14.91M -$109.45 N/A

Does the media favor NIVF or BIAF?

In the previous week, bioAffinity Technologies had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 4 mentions for bioAffinity Technologies and 3 mentions for NewGenIvf Group. bioAffinity Technologies' average media sentiment score of 1.01 beat NewGenIvf Group's score of 0.96 indicating that bioAffinity Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bioAffinity Technologies 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GXAI or NIVF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, GXAI or NIVF?

NewGenIvf Group has higher revenue and earnings than Gaxos.ai. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gaxos.ai $1.93M 2.51 -$3.90M -$0.50 N/A NewGenIvf Group $4.73M 0.47 $9.88M N/A N/A

NewGenIvf Group (NIVF) Competitors

$1.06 -0.05 (-4.50%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.05 -0.01 (-1.32%)

As of 09/11/2026 07:50 PM Eastern

Compare

NIVF vs. MGRX, AIDX, BMGL, BIAF, and GXAI

Should you buy NewGenIvf Group stock or one of its competitors? NewGenIvf Group's main competitors and comparable companies include Mangoceuticals (MGRX), 20/20 Biolabs (AIDX), Basel Medical Group (BMGL), bioAffinity Technologies (BIAF), and Gaxos.ai (GXAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does NewGenIvf Group compare to Mangoceuticals?

NewGenIvf Group (NASDAQ:NIVF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, NewGenIvf Group and NewGenIvf Group both had 3 articles in the media. NewGenIvf Group's average media sentiment score of 0.96 beat Mangoceuticals' score of 0.96 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mangoceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NewGenIvf Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.47	$9.88M	N/A	N/A
Mangoceuticals	$460K	18.89	-$20.64M	-$1.01	N/A

NewGenIvf Group has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

NewGenIvf Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. NewGenIvf Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NewGenIvf Group beats Mangoceuticals on 8 of the 10 factors compared between the two stocks.

How does NewGenIvf Group compare to 20/20 Biolabs?

NewGenIvf Group (NASDAQ:NIVF) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

NewGenIvf Group has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.47	$9.88M	N/A	N/A
20/20 Biolabs	$2.05M	3.49	-$3.74M	-$0.54	N/A

In the previous week, NewGenIvf Group had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for NewGenIvf Group and 1 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.87 beat NewGenIvf Group's score of 0.96 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Overall Sentiment
NewGenIvf Group	Positive
20/20 Biolabs	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

66.2% of NewGenIvf Group shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 792.86%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than NewGenIvf Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NewGenIvf Group and 20/20 Biolabs tied by winning 5 of the 10 factors compared between the two stocks.

How does NewGenIvf Group compare to Basel Medical Group?

NewGenIvf Group (NASDAQ:NIVF) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

NewGenIvf Group has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.47	$9.88M	N/A	N/A
Basel Medical Group	$8.90M	0.82	-$9.50M	N/A	N/A

NewGenIvf Group has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NewGenIvf Group had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for NewGenIvf Group and 2 mentions for Basel Medical Group. NewGenIvf Group's average media sentiment score of 0.96 beat Basel Medical Group's score of 0.94 indicating that NewGenIvf Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Basel Medical Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of NewGenIvf Group shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Basel Medical Group	N/A	N/A	N/A

Summary

NewGenIvf Group beats Basel Medical Group on 5 of the 8 factors compared between the two stocks.

How does NewGenIvf Group compare to bioAffinity Technologies?

NewGenIvf Group (NASDAQ:NIVF) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

NewGenIvf Group has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. NewGenIvf Group's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NewGenIvf Group has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, suggesting that its share price is 211% less volatile than the broader market.

NewGenIvf Group has higher earnings, but lower revenue than bioAffinity Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.47	$9.88M	N/A	N/A
bioAffinity Technologies	$6.16M	0.77	-$14.91M	-$109.45	N/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than NewGenIvf Group. MarketBeat recorded 4 mentions for bioAffinity Technologies and 3 mentions for NewGenIvf Group. bioAffinity Technologies' average media sentiment score of 1.01 beat NewGenIvf Group's score of 0.96 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bioAffinity Technologies	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NewGenIvf Group beats bioAffinity Technologies on 7 of the 11 factors compared between the two stocks.

How does NewGenIvf Group compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NewGenIvf Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. NewGenIvf Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
NewGenIvf Group	N/A	N/A	N/A

Gaxos.ai has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, NewGenIvf Group has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NewGenIvf Group had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 3 mentions for NewGenIvf Group and 2 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 1.43 beat NewGenIvf Group's score of 0.96 indicating that Gaxos.ai is being referred to more favorably in the media.

Company	Overall Sentiment
Gaxos.ai	Positive
NewGenIvf Group	Positive

NewGenIvf Group has higher revenue and earnings than Gaxos.ai.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	2.51	-$3.90M	-$0.50	N/A
NewGenIvf Group	$4.73M	0.47	$9.88M	N/A	N/A

Summary

NewGenIvf Group beats Gaxos.ai on 8 of the 11 factors compared between the two stocks.

Get NewGenIvf Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NIVF vs. The Competition

Export

Metric	NewGenIvf Group	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.23M	$9.84B	$7.16B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.17%
P/E Ratio	N/A	33.53	274.94	25.36
Price / Sales	0.47	4.89	686.57	116.78
Price / Cash	N/A	125.15	76.65	51.52
Price / Book	0.00	5.29	10.33	6.20
Net Income	$9.88M	$313.25M	$3.50B	$358.50M
7 Day Performance	-7.02%	-1.26%	-3.32%	-2.35%
1 Month Performance	-35.73%	-1.53%	-0.53%	-3.23%
1 Year Performance	-99.90%	58.44%	23.51%	8.79%

NewGenIvf Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NIVF NewGenIvf Group	2.6476 of 5 stars	$1.06 -4.5%	N/A	-99.9%	$2.23M	$4.73M	N/A	N/A	Short Interest Decrease Gap Up
MGRX Mangoceuticals	1.1201 of 5 stars	$0.42 +1.0%	N/A	-82.3%	$8.95M	$315.23K	N/A	3	News Coverage Short Interest Decrease Gap Up
AIDX 20/20 Biolabs	2.816 of 5 stars	$0.58 +0.0%	$5.00 +765.1%	N/A	$7.38M	$2.05M	N/A	14	News Coverage Gap Up
BMGL Basel Medical Group	0.6769 of 5 stars	$4.68 -2.1%	N/A	-80.3%	$7.32M	$14.55M	N/A	36	News Coverage Positive News Analyst Downgrade Gap Down
BIAF bioAffinity Technologies	0.9285 of 5 stars	$10.61 +18.8%	N/A	-93.5%	$6.36M	$6.16M	N/A	10	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NIVF) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewGenIvf Group (NIVF) Competitors

NIVF vs. MGRX, AIDX, BMGL, BIAF, and GXAI

How does NewGenIvf Group compare to Mangoceuticals?

Summary

How does NewGenIvf Group compare to 20/20 Biolabs?

Summary

How does NewGenIvf Group compare to Basel Medical Group?

Summary

How does NewGenIvf Group compare to bioAffinity Technologies?

Summary

How does NewGenIvf Group compare to Gaxos.ai?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIVF vs. The Competition

NewGenIvf Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewGenIvf Group (NIVF) Competitors

NIVF vs. MGRX, AIDX, BMGL, BIAF, and GXAI

How does NewGenIvf Group compare to Mangoceuticals?

Does the media refer more to NIVF or MGRX?

Do insiders & institutionals believe in NIVF or MGRX?

Which has better valuation and earnings, NIVF or MGRX?

Which has more volatility & risk, NIVF or MGRX?

Is NIVF or MGRX more profitable?

Do analysts rate NIVF or MGRX?

Summary

How does NewGenIvf Group compare to 20/20 Biolabs?

Which has stronger earnings & valuation, NIVF or AIDX?

Does the media prefer NIVF or AIDX?

Is NIVF or AIDX more profitable?

Do insiders and institutionals believe in NIVF or AIDX?

Do analysts recommend NIVF or AIDX?

Summary

How does NewGenIvf Group compare to Basel Medical Group?

Which has better valuation and earnings, NIVF or BMGL?

Which has more risk and volatility, NIVF or BMGL?

Do analysts rate NIVF or BMGL?

Does the media favor NIVF or BMGL?

Do insiders & institutionals hold more shares of NIVF or BMGL?

Is NIVF or BMGL more profitable?

Summary

How does NewGenIvf Group compare to bioAffinity Technologies?

Is NIVF or BIAF more profitable?

Do insiders & institutionals believe in NIVF or BIAF?

Which has more risk & volatility, NIVF or BIAF?

Which has preferable earnings and valuation, NIVF or BIAF?

Does the media favor NIVF or BIAF?

Do analysts recommend NIVF or BIAF?

Summary

How does NewGenIvf Group compare to Gaxos.ai?

Do insiders & institutionals believe in GXAI or NIVF?

Is GXAI or NIVF more profitable?

Which has more risk & volatility, GXAI or NIVF?

Do analysts recommend GXAI or NIVF?

Does the media refer more to GXAI or NIVF?

Which has better earnings and valuation, GXAI or NIVF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIVF vs. The Competition

NewGenIvf Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools